ASS1 and glioblastoma: Since metabolomics allows for the global assessment of cellular states, this study was carried out to determine if ASS negative and ASS positive GBM have distinct basal metabolic phenotypes that could be exploited for their non-invasive detection in vivo and reveal new therapeutic strategies for the treatment of these GBM phenotypes.